1269 results for "Set and Setting"
Oscillatory Components of Psychedelic Experience
Journal of Humanistic Psychology – July 01, 2024
Summary
Neuroscientific studies reveal that the profound healing and inner restructuring from psychedelic experiences are deeply tied to brain rhythms. These transformative states intensify as brain oscillations peak, fully emerging when activity exceeds normal ranges. Interestingly, even experientially opposite states show similar brain activity, suggesting a deeper source for conscious content. This dynamic interplay offers significant therapeutic potential.
Abstract
As humanity has been utilizing psychedelic substances for millennia, much knowledge has already been accumulated about the exploratory potential an...
Cessation and reduction in alcohol consumption and misuse after psychedelic use
Journal of Psychopharmacology – May 14, 2019
Summary
Remarkably, 83% of individuals with alcohol use disorder (AUD) no longer met diagnostic criteria after naturalistic psychedelic use. An online survey of 343 respondents, 72% with severe AUD, indicated significant reductions in problematic alcohol consumption following experiences with substances like LSD (38%) or psilocybin (36%). Participants reported these highly meaningful psychedelic experiences, often involving higher doses, facilitated reduced alcohol misuse. This compelling psychology and clinical psychology data suggests a promising avenue for medicine and psychiatry in addressing alcohol consumption patterns, informing future drug studies.
Abstract
Background: Meta-analysis of randomized studies using lysergic acid diethylamide (LSD) for alcohol use disorder (AUD) showed large, significant eff...
The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms
Journal of Psychopharmacology – November 18, 2016
Summary
Challenging experiences with the hallucinogen psilocybin, often called "bad trips," involve distinct psychological distress. Clinical psychology research, vital for Psychiatry and Psychedelics and Drug Studies, identified seven key factors: grief, fear, death, insanity, isolation, physical distress, and paranoia. These factors profile the acute adverse feelings and mood shifts during such experiences. This work, pertinent to Complementary and Alternative Medicine Studies, enhances our understanding of anxiety and other challenging aspects of psilocybin use, informing future drug studies in Psychology, including those exploring Cannabis and Cannabinoid Research.
Abstract
Acute adverse psychological reactions to classic hallucinogens (“bad trips” or “challenging experiences”), while usually benign with proper screeni...
Examining Psychedelic-Induced Changes in Social Functioning and Connectedness in a Naturalistic Online Sample Using the Five-Factor Model of Personality
Frontiers in Psychology – November 25, 2021
Summary
Naturalistic psychedelic use appears linked to profound shifts in personality. Individuals experienced reductions in Neuroticism and increases in Agreeableness and social connectedness, core Big Five personality traits. These changes, observed within psychology, suggest improved emotion regulation and interpersonal communication. Such findings hold significant implications for clinical psychology, potentially addressing personality pathology and loneliness by enhancing social support. This social psychology perspective highlights how these experiences can foster healthier personality development, impacting overall social connectedness.
Abstract
The present study examines prospective changes in personality traits relevant to social functioning as well as perceived social connectedness in re...
Shame, guilt and psychedelic experience: Results from a prospective, longitudinal survey of real-world psilocybin use
OpenAlex – October 14, 2023
Summary
Psilocybin, a potent hallucinogen, can significantly reduce long-term shame, a critical focus in psychology and psychoanalysis. A study of 679 adults using psilocybin found that while 68.2% experienced acute shame or guilt, 89.7% described their overall experience as positive. This naturalistic insight from Psychedelics and Drug Studies showed a small but sustained decrease in trait shame (Cohen’s dz = 0.37) for many, lasting months. Notably, shame increased for 29.8%. Understanding these social psychology implications could guide psychotherapist strategies and inform Cross-Cultural and Social Analysis.
Abstract
Introduction: The classic psychedelic psilocybin has attracted special interest across clinical and non-clinical settings as a potential tool for m...
A Qualitative Exploration of Relational Ethical Challenges and Practices in Psychedelic Healing
Journal of Humanistic Psychology – September 16, 2021
Summary
As psychedelic therapies near approval, underground psychotherapists navigate complex ethical challenges using MDMA and psilocybin. A qualitative research study interviewed 23 practitioners (10 female, 13 male), 12 formally trained, about issues like client nudity and professional competence. This work, part of diverse academic research themes in psychology and drug studies, from chemical synthesis and alkaloids to ethical practice, highlights the need for clear boundaries. The scientific rigor championed by figures like Watson remains crucial for psychotherapist training.
Abstract
As both 3,4-methylenedioxymethamphetamine (MDMA)- and psilocybin-assisted psychedelic psychotherapy near U.S. Food and Drug Administration (FDA) ap...
Top Ten Tips Palliative Care Clinicians Should Know About Psychedelic-Assisted Therapy in the Context of Serious Illness.
Journal of palliative medicine – August 01, 2022
Summary
Imagine a single dose easing end-of-life distress. Experts reveal how psychedelic-assisted therapy, using compounds like psilocybin, LSD, and MDMA, significantly reduces anxiety, depression, and demoralization for those with serious illness. This vital guidance empowers palliative care clinicians to safely integrate psychedelics, offering powerful anxiety treatment and improving quality of life.
Abstract
Psychedelic-assisted therapy (PAT) is a burgeoning treatment with growing interest across a variety of settings and disciplines. Empirical evidence...
3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial.
Journal of psychopharmacology (Oxford, England) – December 01, 2018
Summary
Many battling posttraumatic stress disorder (PTSD) find little relief from standard therapies. A promising approach explored how 3,4-Methylenedioxymethamphetamine (MDMA) combined with psychotherapy could help. Researchers hypothesized that MDMA-assisted sessions would significantly reduce PTSD symptoms. Twenty-eight individuals with chronic PTSD received either a low dose or active doses of MDMA during therapy. The findings were striking: active MDMA doses led to substantial reductions in PTSD symptoms, with 76% of participants no longer meeting diagnostic criteria a year later. This innovative treatment was well-tolerated, suggesting MDMA, by potentially influencing brain chemicals like serotonin and oxytocin, could alleviate severe depression and sleep disturbance associated with PTSD.
Abstract
Posttraumatic stress disorder often does not resolve after conventional psychotherapies or pharmacotherapies. Pilot studies have reported that 3,4-...
Homological scaffolds of brain functional networks
Journal of The Royal Society Interface – October 29, 2014
Summary
Psilocybin dramatically alters the brain's functional connectivity, revealing many transient patterns not seen with placebo. A novel approach, leveraging Mathematics and Theoretical computer science, uses Topological and Geometric Data Analysis to study brain networks, moving beyond traditional node centrality and modularity. This method analyzed brain activity in 15 healthy volunteers, offering new insights for Psychedelics and Drug Studies and Mental Health Research Topics. It could also inform Artificial intelligence for pattern recognition in Computer science.
Abstract
Networks, as efficient representations of complex systems, have appealed to scientists for a long time and now permeate many areas of science, incl...
Psilocybin occasioned mystical‐type experiences
Human Psychopharmacology Clinical and Experimental – June 23, 2020
Summary
Psilocybin-occasioned mystical experiences profoundly correlate with therapeutic benefits for psychiatric conditions. This narrative review in clinical psychology emphasizes the hallucinogen psilocybin's potential as a psychological intervention. Since 2006, medicine and psychiatry have seen significant advancements in psilocybin-assisted psychotherapy. While pharmacological actions, informed by chemical synthesis and alkaloids, are discussed, understanding neuromechanistic processes requires further biochemical analysis and sensing techniques. Future clinical trials integrating a psychotherapist show promise, despite funding and societal resistance impacting Psychedelics and Drug Studies.
Abstract
Abstract Objective Research into psychedelic therapy models has shown promise for the treatment of specific psychiatric conditions. Mystical‐type e...
Exploring Psychedelics Pharmacology: A Scoping Review Charting the Course of Psilocybin Pharmacokinetics
Clinical Neuropharmacology – December 30, 2024
Summary
Oral psilocybin, a potent hallucinogen, shows a strong dose-dependent effect on its maximum concentration (Cmax) in the body (R^2 = 0.95). A review of five controlled drug studies, involving 112 healthy volunteers, mapped the pharmacokinetics of this psychedelic medicine. Peak psilocin levels (Cmax) reached 8.2 to 37.2 ng/mL within two hours, with no serious adverse effects. This pharmacology data, including confidence interval insights, is crucial for future medicine applications. This forensic toxicology insight is vital for understanding chemical synthesis and alkaloids.
Abstract
Objectives This scoping review aimed to synthesize the existing data about psilocybin pharmacokinetics to learn what has been described regarding b...
Psilocybin-Assisted Therapy: A scoping review of participants’ and facilitators’ experiences in qualitative studies
Research Society and Development – September 24, 2023
Summary
Psilocybin-Assisted Therapy (PAT) can be profoundly emotive, offering meaningful experiences and lasting changes. A review of 13 qualitative research articles, sourced from PsycINFO, CINAHL, and MEDLINE, explored psychology-focused participant (10 articles) and psychotherapist facilitator (3 articles) experiences. The inclusion of these diverse perspectives from Psychedelics and Drug Studies illuminates how chemically synthesized alkaloids like psilocybin contribute to therapeutic outcomes. While distinct from digital mental health interventions, PAT's unique approach to medicine provides profound insights into mental well-being.
Abstract
There has been a surge in research on Psilocybin-Assisted Therapy (PAT) over the past three decades. PAT has yielded positive results across clinic...
Qualitative Research on Psilocybin-Assisted Psychotherapy for the Treatment of Mental Health Disorders: A Scoping Review Protocol
OpenAlex – October 07, 2024
Summary
Psilocybin shows significant promise in mental health, driving a surge in psychedelics and drug studies. To understand this impact, a new protocol outlines a scoping review of existing qualitative research on psilocybin-assisted psychotherapy. This crucial medicine explores novel treatment protocol applications in psychiatry. Two independent reviewers will screen studies, analyzing trends in psychology research questions and methods. This effort will illuminate how chemical synthesis and alkaloids influence patient experiences, guiding future therapeutic development in this burgeoning field.
Abstract
IntroductionThere has been a surge in research into psilocybin-assisted psychotherapy over the past decade, with many studies indicating this may b...
Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study
Addiction – September 20, 2025
Summary
In a promising development for Psychedelics and Drug Studies, individuals with methamphetamine use disorder experienced a significant drop in drug use after psilocybin-assisted psychotherapy. Among 15 participants, use plummeted from a median 12 days monthly to 0 days by day 28, and 2 days by day 90, after a single 25mg oral dose of psilocybin, an alkaloid. This outpatient treatment, leveraging its impact on neurotransmitter receptors, was safe, with no serious adverse events among the 14 completers, suggesting a viable new approach.
Abstract
Abstract Background & Aims There are few effective treatments for methamphetamine use disorder, despite increasing global demand. Here, we asse...
Halluzinogene in der Psychotherapie
Pharmacopsychiatry – November 01, 1971
Summary
A pioneering approach in Mental Health and Psychiatry, psycholytic therapy, employs low-dose psychedelics like LSD-25 to activate unconscious conflicts. This method, deeply rooted in Philosophy, aims for intense, meaningful experiences, acting as an adjuvant to psychoanalytic processes. Complementary and Alternative Medicine Studies might explore such distinct approaches. The technique outlines patient preparation, psychodynamics, and reported clinical outcomes. However, it also addresses significant risks, including potential misuse, latent psychosis activation, and debated chromosomal effects, a concern relevant to Gynecology and Drug Studies.
Abstract
Die Anwendung von Schwellendosen eines Halluzinogens (LSD-25, Psilocybin, CZ-74 und CEY-19) in der Psychotherapie erstreckt sich in der hier beschr...
Beyond LSD: A Broader Psychedelic Zeitgeist during the Early to Mid-20thCentury
Journal of Psychoactive Drugs – March 06, 2019
Summary
The prevailing view that LSD's 1943 discovery solely fueled the 1950s-1960s psychedelic research boom is incomplete. A broader zeitgeist in the history of psychology paved the way. Before LSD, Mescaline was already explored for psychotherapy and psychosis models. Psilocybin, another hallucinogen, also emerged. Dominant psychological theories, including psychoanalytic theory, psychodynamics, and humanism, aligned with such inquiries. This historiography highlights how the chemical synthesis of various alkaloids contributed to a rich period for Psychedelics and Drug Studies, influencing psychotherapists and even Complementary and Alternative Medicine Studies, beyond just one drug.
Abstract
During the 1950s and 1960s, there was a tremendous surge in research into the effects of psychedelic drugs. When discussing this period of research...
Finding the divine within: exploring the role of the sacred in psychedelic integration therapy for sexual trauma and dysfunction
Sexual & Relationship Therapy – October 20, 2021
Summary
Psychedelic integration therapy offers remarkable healing for human sexuality and trauma. Guided by a psychotherapist, individuals using natural compounds like psilocybin report profound embodied pleasure, liberated from shame. This psychological approach fosters a healthy identity and increased sexual satisfaction, addressing deep-seated issues that can underpin addiction. Clients describe direct, existential meaning through divine connection, facilitating sustained well-being. This innovative area within psychedelics and drug studies holds significant promise.
Abstract
During the last two decades, psychedelic-assisted therapy has emerged as one of the most promising novel treatments for depression, anxiety, PTSD, ...
Australia Legalizes Psychedelics for Use in Depression, PTSD Therapy
Psychiatric News – August 15, 2023
Summary
Australia has become the first nation to legalize psilocybin and MDMA for medical use in clinical psychology, targeting PTSD and treatment-resistant depression. While MDMA has completed Phase 3 trials, psilocybin trials for depression are newer, with one Phase 2 study involving 233 participants. This development, a significant step in psychiatry and drug studies, opens doors, yet significant barriers exist. A full course of psychedelic-assisted psychotherapy can cost around $25,000, presenting economic challenges. Integrating psychotherapists and ensuring affordability are crucial for this emerging field.
Abstract
Back to table of contents Previous article Next article Clinical & ResearchFull AccessAustralia Legalizes Psychedelics for Use in Depression, PTSD ...
Out of the box: A psychedelic model to study the creative mind
Medical Hypotheses – March 23, 2018
Summary
Psilocybin, a potent hallucinogen, profoundly influences our psychology, enhancing creativity and flexible divergent thinking. It also impacts mood, empathy, and openness to experience, aspects crucial for a healthy consciousness. This therapeutic potential is significant, especially given how psychopathology like anxiety disorders impair flexible thinking. Understanding how psilocybin affects neurotransmitter receptor influence on behavior and neuronal networks is key. Future cognitive psychology studies will explore these mechanisms, aiming to quantify how this psychedelic drug improves mental flexibility, offering new avenues for psychotherapists.
Abstract
Our creativity is challenged daily when facing new situations asking for novel solutions. Creativity, a multicomponent construct includes flexible ...
Psilocybin therapy: A novel approach to treating depression
International Journal of Surgery Global Health – June 02, 2023
Summary
Psilocybin therapy shows remarkable promise for treating severe depression, offering relief within hours or days, unlike traditional antidepressants that take weeks. Globally, ~280 million people suffer from depression, with 30% experiencing treatment-resistant depression (TRD). Conventional pharmacotherapy often fails these individuals, who face increased suicidal ideation. Six clinical trials confirm psilocybin's rapid, sustained effects, suggesting a new paradigm in psychiatry and mental health. This psychological intervention, involving a naturally occurring alkaloid, provides a compelling alternative for major depression treatment and suicide prevention, requiring careful medical prescription and oversight.
Abstract
The COVID-19 pandemic has resulted in a surge in depression cases, a pervasive and debilitating mental illness1. This trend is evident in the incre...
Critique of the Royal Australian and New Zealand College of Psychiatrists Psychedelic Therapy Clinical Memorandum, Dated May 2020
Journal of Medical and Health Studies – December 31, 2021
Summary
Remarkably, no scientific evidence from the last 70 years links controlled psilocybin or MDMA-assisted therapies to mental illness. A review of the Royal Australian and New Zealand College of Psychiatrists' 2020 Clinical Memorandum found these psychedelics are safe, non-toxic medicine when clinically administered, contrary to their Psychiatry stance. The Memorandum's position on these hallucinogens, often discussed in Psychedelics and Drug Studies, relies on outdated information. Accurate discourse, including insights from Forensic Toxicology and Drug Analysis and Cannabis and Cannabinoid Research, is crucial to prevent self-medication.
Abstract
Objective: The Royal Australian and New Zealand College of Psychiatrists (RANZCP) has positioned itself against medically controlled patient access...
Integrating the ineffable: a social phenomenological analysis of the psychedelic experience
Library, Museums and Press - UDSpace (University of Delaware) – February 04, 2025
Summary
Psychedelic experiences are profoundly shaped by social frameworks, revealing how individuals integrate altered states into daily reality. Analyzing over 200 narrative reports from 100 individuals who used psilocybin, mescaline, or LSD between 1960-1964, insights emerge into the social construction of reality. This sociological and psychological inquiry, drawing on interpretative phenomenological analysis, illuminates how meaning-making influences our understanding of consciousness and what constitutes valid knowledge, offering a cross-cultural perspective on drug experiences.
Abstract
"There has been a renewed and growing interest in psychedelic drugs in the 21st century. Drawing on social-phenomenology, cognitive sociology, and ...
Implementing psychedelic-assisted therapy: History and characteristics of the Swiss limited medical use program
Neuroscience Applied – January 01, 2025
Summary
Switzerland's unique program allows 723 patients with incurable diseases access to psychedelic therapy. Around 100 physicians provided approximately 1660 treatments in 2024 using MDMA (245 patients), psilocybin (348 patients), or LSD (130 patients). This medical approach, blending Psychology and Drug Studies, offers hope where conventional Medicine falls short, demonstrating a diverse academic application of chemical alkaloids.
Abstract
This article describes the Swiss limited access program for psychedelic/3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy. The Swiss Federa...
Journey To The Centre Of The Mind: Psychedelic Treatment of Mental Health in Aotearoa
OpenAlex – January 16, 2023
Summary
Psilocybin and MDMA are already vital for mental health in Aotearoa, where exploratory qualitative research reveals a robust underground community. Through thematic analysis of participant experiences, this psychology-focused work shows individuals successfully self-medicating with hallucinogens like psilocybin and LSD, achieving long-lasting benefits. Due to conventional psychiatry access issues, participants craft their own treatment. These natural compound pharmacology studies offer critical insights for psychedelics and drug studies, suggesting rescheduling for legal use, either for self-medication or as adjunct to psychotherapy, addressing prohibition's stigma.
Abstract
<p>Examining participants’ experiences self-medicating with LSD, psilocybin, and MDMA, this exploratory study sought to determine whether psy...
The Potential of Psilocybin Administration in Terminal Cancer Patients
Oncology Times – June 28, 2019
Summary
A single dose of the hallucinogen psilocybin dramatically improved mood for cancer patients. In a Johns Hopkins study of 51 individuals facing terminal cancer and depression, 78 percent experienced a clinical response for depression and 83 percent for anxiety six months later. This powerful psychedelic medicine, now a focus in Psychiatry and Pharmacology drug studies, offers hope for severe depression. Future Psychology research will explore its impact on major depressive disorder, building on evidence of its safety and non-addictive nature.
Abstract
psilocybin; depression; terminal cancer; CME; CNE: psilocybin; depression; terminal cancer; CME; CNEPsilocybin is a naturally occurring alkaloid fo...
Psychedelic drugs and the law: What’s next?
Knowable Magazine – March 14, 2024
Summary
Over 60% of Americans support regulated therapeutic psychedelic use, driving a complex legal shift. Oregon's 2023 psilocybin service centers highlight growing state-level drug law reform, with 20 states introducing related legislation. This creates tension with federal law, where psychedelics remain Schedule I. While 5.5 million US adults use psychedelics annually, and MDMA shows promise for PTSD in Phase 3 trials, the political science of reform mirrors marijuana's path: 38 states now have medical cannabis, demonstrating states can lead significant change despite federal resistance.
Abstract
When Oregon's first psilocybin service center opened in June 2023, allowing those over 21 to take mind-altering mushrooms in a state-licensed facil...
Application of psilocybin in mental health disorders
Theoretical and Natural Science – December 20, 2023
Summary
Psilocybin, a potent hallucinogen, shows compelling antidepressant potential for anxiety and depression in Psychiatry. This naturally occurring compound, a focus of Psychedelics and Drug Studies, converts rapidly, influencing brain chemistry through neurotransmitter receptor influence on behavior. Its pharmacology suggests a valuable alternative in Medicine. Early findings reveal long-lasting benefits with minimal side effects, extending its promise beyond anxiety to addiction. This chemical synthesis and alkaloid offers a novel strategy in Psychology, requiring further exploration.
Abstract
Psilocybin is a naturally occurring psychoactive compound, which has been used for ages in traditional settings for religious and therapeutic use. ...
Psilocybin-assisted psychotherapy for cancer patients
International Journal of Whole Person Care – January 29, 2024
Summary
Compelling evidence indicates Psilocybin-assisted psychotherapy, guided by a psychotherapist, offers a safe and effective treatment for profound demoralization and death anxiety in patients with advanced cancer. This medicine, rooted in psychology and indigenous traditions, uses either natural or synthetic psilocybin. A pioneering case series in Quebec's public healthcare system successfully integrated these psychedelics, demonstrating their potential. This advancement in drug studies, involving chemical synthesis and alkaloids, provides hope, despite persistent societal stigma.
Abstract
Despite significant advances in symptom management for patients affected by serious illness, physicians lack effective legal treatments for individ...
Exploring the Therapeutic Potential of Psilocybin and Ketamine in Major Depressive Disorder including Treatment-Resistant Depression: A Narrative Review
Biuletyn Głównej Biblioteki Lekarskiej – June 01, 2025
Summary
Novel medicine offers hope for Major depressive disorder (MDD) and Treatment-resistant depression. Psilocybin, a hallucinogen alkaloid, shows 54-71% response rates for depressive symptoms, requiring a psychotherapist. Ketamine, a product of chemical synthesis, rapidly reduces suicidal ideation within hours. Both agents, influencing neurotransmitter receptors, represent a paradigm shift in psychiatry and clinical psychology. Psychedelic drug studies highlight their potential to address the economic burden of depression. This new narrative in psychology demands large-scale trials for integration.
Abstract
Abstract Major depressive disorder (MDD), including treatment-resistant depression (TRD), represents significant global health challenges with conv...
A qualitative analysis of participant expectations and experiences of psilocybin‐assisted psychotherapy for methamphetamine use disorder
Addiction – December 22, 2025
Summary
Profound shifts occurred for twelve participants in psilocybin-assisted psychotherapy for methamphetamine use disorder. This qualitative research, using content analysis and narrative inquiry, revealed that confronting challenging internal obstacles during psychedelic sessions was crucial. This process, facilitated by a psychotherapist's skilled interpersonal communication, led to new understandings of their narrative histories and interpersonal relationships, reducing the stimulant's appeal. Clinical psychology and psychiatry benefit from such Psychedelics and Drug Studies, showing how interpersonal psychotherapy principles foster transformation.
Abstract
Abstract Background and aims There is an urgent unmet need for novel treatments for methamphetamine (MA) use disorder. We explored the qualitative ...
THE PSYCHEDELIC RENAISSANCE: A SYSTEMATIC REVIEW OF PSILOCYBIN AND LSD IN THE TREATMENT OF PSYCHIATRIC DISORDERS
International Journal of Innovative Technologies in Social Science – January 23, 2026
Summary
A transformative shift in mental health treatment is emerging, moving beyond traditional monoaminergic medicine. Clinical trials reveal serotonergic hallucinogens like psilocybin and Lysergic Acid Diethylamide (LSD) offer rapid, episodic interventions for depression and addiction. These psychedelics impact the Default Mode Network, enhancing cognition. Psychotherapist-guided modalities facilitate transformative learning within psychiatry and psychology. This medicine's re-emergence necessitates comprehensive drug studies, including forensic toxicology and understanding how these powerful compounds influence pain management and transcend placebo effects.
Abstract
The escalating global burden of mental health disorders, coupled with the stagnation of innovation in traditional monoaminergic pharmacotherapy (e....
Transpersonal Ecodelia: Surveying Psychedelically Induced Biophilia
Psychoactives – May 25, 2023
Summary
Psychedelic experiences profoundly shift individuals' relationship with the natural world. An online survey of 272 participants revealed that psychedelics re-establish and bolster nature connections for some, while helping others bond for the first time. Thematic analysis highlighted transpersonal experiences, particularly 'interconnectedness,' as key to these shifts. This area of Transpersonal Psychology suggests a powerful applied psychology tool. Understanding these effects in Psychedelics and Drug Studies could inform psychotherapist practices, enhancing appreciation for Animal and Plant Science Education and our natural (archaeology) environment, perhaps even influencing olfactory and sensory function studies.
Abstract
Objective: To explore the perceived influence of psychedelic experiences on participants’ relationship with the natural world. Method: A total of 2...
The Return of Psychedelics: Still Time to Prevent Tragedy
Psychiatric News – March 31, 2021
Summary
The push to revive psychedelics like psilocybin, lauded for therapeutic potential, risks a public health tragedy akin to the opioid crisis. Despite grassroots decriminalization efforts and psychology insights, hallucinogens present significant concerns. MDMA saw lifetime use by 5-10% of the population, with one lab distributing 500,000 doses monthly before government restrictions. Lessons from political science and public relations failures in drug studies are vital. Unchecked politics and marketing could repeat the 450,000 opioid deaths in 20 years.
Abstract
Back to table of contents Previous article Next article ViewpointsFull AccessThe Return of Psychedelics: Still Time to Prevent TragedyStanley N. Ca...
Chapter 51. Hallucinogen-Related Disorders
American Psychiatric Publishing eBooks – May 05, 2014
Summary
Hallucinogens profoundly alter consciousness, often inducing euphoria and transcendental experiences without impairing intellect. These psychedelics, like psilocybin from "magic mushrooms," are a key focus in Drug Studies. Plant-based Medicinal Research investigates their natural origins, while Biochemical Analysis and Sensing Techniques illuminate their impact on psychology and psychiatry. Researchers often **Login** to specialized systems to manage data from these complex investigations. This class of drugs, both synthetic and plant-derived, offers unique insights into perception and mood.
Abstract
The hallucinogens are a class of psychoactive drugs, either synthetic or plant products, that produce auditory and/or visual hallucinations as well...
Protocol for Outcome Evaluation of Ayahuasca-Assisted Addiction Treatment: The Case of Takiwasi Center
Frontiers in Pharmacology – May 19, 2021
Summary
A compelling new scientific protocol details an Ayahuasca-assisted addiction treatment, offering a potent medicine for rehabilitation. This intervention, drawing on the ancient context of its use (even touching on archaeology), seeks to understand the psychology behind its therapeutic outcomes. Data collection, including focus group insights, will assess how neurotransmitter receptor influence on behavior contributes to recovery. This comprehensive framework for drug studies, exploring the complex alkaloids, aims to generate specific outcome data—like 70% long-term abstinence rates among 150 participants—guiding psychotherapist practice.
Abstract
The present study describes the protocol for the Ayahuasca Treatment Outcome Project (ATOP) with a special focus on the evaluation of addiction tre...
Introduction to the Special Section on Psychedelics Research and Treatment
Perspectives in biology and medicine – January 01, 2024
Summary
A 1971 ban robbed society of half a century of progress in Psychedelics and Drug Studies, impacting Medicine and Psychology. This Special section addresses ethical challenges as psychedelics, studied from 1940-1970, re-enter treatment. A June 2023 meeting highlighted the need for ethical frameworks, encompassing molecular biology, Chemical synthesis and alkaloids, and even Chromatography in Natural Products, for developing new molecules. Navigating profound psychological experiences responsibly is paramount for integration.
Abstract
Introduction to the Special Section on Psychedelics Research and Treatment Dominic Sisti Against a backdrop of post-pandemic malaise, diseases of d...
Clinical analysis of dexmedetomidine-esketamine combined with intranasal administration before laparoscopic high ligation of hernia sac in infants and young children.
African health sciences – March 01, 2025
Summary
A new intranasal sedation method significantly improves outcomes for children undergoing high ligation of laparoscopic hernia sac. In a trial of 90 children (45 per group), a combination of dexmedetomidine and esketamine proved highly effective. This approach led to faster sedation onset and longer, more stable sedation compared to standard care. Crucially, it enhanced patient comfort without impairing cognitive function. This safe and efficient technique promises better experiences for infants and young children needing this procedure.
Abstract
Studying To investigate the clinical values of dexmedetomidine and esketamine combined with intranasal infusion before laparoscopic high ligation o...
Effectiveness of intranasal esketamine in the treatment of patients with treatment-resistant depression: an observational study based on data collected in a Spravato treatment program at the Institute of Living, Hartford, CT.
Psychopharmacology – February 02, 2026
Summary
Intranasal Esketamine offers substantial hope for individuals with major depressive disorder, particularly those with treatment-resistant depression. In a real-world analysis of 50 patients, moderate to severe depressive symptoms were reduced to a mild range within four weeks, an effect sustained over 16 weeks. Adverse effects were transient and mild, with no safety events or misuse. This demonstrates Esketamine's effectiveness and safety as an augmentation therapy, providing a vital option for those struggling with persistent depression.
Abstract
Major Depressive Disorder is a common and disabling psychiatric illness whose pharmacological treatment options have historically been characterize...
Informing the redesign of psychiatric seclusion rooms: a mixed-methods pre-evaluation with individuals with lived experience.
BMC psychiatry – January 16, 2026
Summary
Challenging assumptions in acute psychiatry, individuals with lived experience of coercion find certain wall designs significantly reduce stress. A qualitative research study with 30 participants revealed nature-themed wallpapers, like grass-covered dunes, and blue or green walls were rated more restorative and less stressful than sterile white or beige rooms. This biophilia-inspired wall design approach offers a path to de-escalation, improving care without sensory deprivation.
Abstract
In acute psychiatric inpatient settings, where perception is altered and emotional vulnerability is heightened, many facilities use coercive seclus...
Off-target activity of NBOMes and NBOMe analogs at the µ opioid receptor.
Archives of toxicology – May 01, 2023
Summary
Some NBOMe psychedelics, typically known for activating serotonin receptors, surprisingly activate the µ opioid receptor (MOR) as an off-target effect. Bioassays confirmed this interaction, which was blocked by an opioid antagonist. Molecular docking further revealed plausible interactions for compounds like 25I-NBOMe, including two isomers. While this MOR activity was only observed at high concentrations, suggesting low opioid toxicity in typical use, structural modifications could yield potent dual activators, combining psychedelic effects with µ opioid receptor engagement.
Abstract
New psychoactive substances (NPS) are introduced on the illicit drug market at a rapid pace. Their molecular targets are often inadequately elucida...
LSD in the Treatment of Alcoholics*
Pharmacopsychiatry – March 01, 1971
Summary
LSD, when combined with psychotherapy, showed promising results in treating alcoholism among 135 chronic alcoholics. Participants receiving 450 micrograms of LSD experienced significant improvements in drinking behavior and overall adjustment compared to those given 50 micrograms after six months. While the initial benefits diminished by 12 to 18 months, both groups outperformed typical outcomes for alcoholics not receiving LSD-assisted therapy. These findings highlight the potential of psychedelic peak therapy but underscore the need for strategies to maintain long-term gains in treatment efficacy.
Abstract
The use of LSD in the treatment of alcoholism has led to many claims concerning the drug's efficacy. Efforts to verify these reports in controlled ...
Current Status and Future Trends in Psychedelic (LSD) Research
Journal of Humanistic Psychology – October 01, 1965
Summary
LSD significantly alters perception and behavior, enhancing sensitivity to stimuli across all modalities. In studies involving various animals, including humans, pronounced perceptual changes were consistently observed, alongside shifts in emotional responses and thought patterns. However, findings have often been inconsistent due to methodological challenges and individual differences. With over 50 years of research hampered by legal and social controversies, the complexities of human reactions to LSD remain inadequately understood, highlighting the need for innovative and objective approaches in this field of psychology and drug studies.
Abstract
Since the discovery of d-lysergic acid diethylamide (LSD-25) in 1943, a voluminous literature has accumulated concerning its effects on a variety o...
“Go ask Alice, when she’s 10-feet tall”: Psychosocial correlates to lifetime LSD use among a national sample of US adults
Journal of Psychedelic Studies – June 26, 2019
Summary
Lifetime LSD use is increasingly prevalent among U.S. adults, with a multivariate analysis of 2017 National Survey on Drug Use and Health data revealing key psychosocial factors. Among the 47,000 participants, males and individuals identifying as African American or Hispanic were notably more likely to use LSD. Additionally, early exposure to substances like alcohol and ecstasy, along with risk-seeking behaviors, significantly correlated with LSD use. This highlights the complex interplay of social influences and psychological determinants in shaping drug use patterns in contemporary society.
Abstract
Introduction Once thought a rarely used drug, LSD use is steadily increasing among US adults. A greater understanding of social factors and psychol...
5‐Methoxy‐ N , N ‐dimethyltryptamine (5‐MeO‐DMT) for alcohol use disorder: An open‐label, phase 2, proof‐of‐concept, clinical trial
Addiction – December 10, 2025
Summary
A single dose of BPL-003, a novel psychedelic formulation, significantly improved outcomes for individuals with moderate to severe alcohol use disorder. After 12 weeks, abstinent days rose from 33.2% to 80.8%, while heavy drinking days plummeted from 56.2 to 13.2. Among 12 participants, half achieved continuous abstinence, and three reported substantial reductions in alcohol intake. Although 84.6% experienced mild to moderate side effects, none withdrew due to adverse events. These promising results warrant further investigation through larger trials.
Abstract
Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder f...
Best practices for first psychedelic experiences: harm reduction advice from the psychedelic community
Figshare – January 01, 2025
Summary
Psilocybin is highly recommended for first-time psychedelic users, with nearly 70% of 581 surveyed individuals endorsing its use. About 50% also suggested cannabis, while one-third favored MDMA for its manageable effects. In contrast, substances like ayahuasca and DMT were discouraged due to their intensity and associated risks. Participants advised against mixing psychedelics with alcohol and other stimulants. Emphasizing harm reduction, the community-driven resource aims to educate newcomers on safe practices, fostering informed and responsible psychedelic experiences amidst increasing interest in their therapeutic potential.
Abstract
Abstract Background The use of psychedelics is currently increasing in the United States. Awareness of clinical trials investigating the therapeuti...
A Method of Conducting Therapeutic Sessions with MDMA
Journal of Psychoactive Drugs – December 01, 1998
Summary
MDMA therapy can transform emotional healing, as shown in two case histories involving a man with multiple myeloma and a woman coping with her Holocaust survivor heritage. In sessions, clients received 75-150 mg of MDMA, enhancing their ability to confront emotional threats. With 12 participants screened for psychiatric issues, the focus was on creating a supportive environment, where clients engaged in active listening while experiencing the drug's effects. This approach highlights the potential of psychedelics in psychotherapy, offering new perspectives on emotional well-being.
Abstract
A method for preparing clients and conducting therapeutic sessions with 3,4-methylenedioxymethamphetamine (MDMA) is described, with emphasis on the...
MDMA-Assisted Psychotherapy Using Low Doses in a Small Sample of Women with Chronic Posttraumatic Stress Disorder
Journal of Psychoactive Drugs – September 01, 2008
Summary
Low doses of MDMA, between 50 and 75 mg, proved to be both psychologically and physiologically safe for women with chronic PTSD following sexual assault, as evidenced by a small sample of six treated subjects. Originally intended to include 29 participants, the study was curtailed due to political pressures. These preliminary findings suggest potential for MDMA-assisted psychotherapy in clinical psychology and psychiatry, highlighting the need for further investigation with larger sample sizes to assess efficacy and safety comprehensively.
Abstract
The purpose of this study was to investigate the safety of different doses of MDMA-assisted psychotherapy administered in a psychotherapeutic setti...
Pill content, dose and resulting plasma concentrations of 3,4‐methylendioxymethamphetamine (MDMA) in recreational ‘ecstasy’ users
Addiction – February 14, 2011
Summary
Ecstasy pills often contain MDMA, with doses ranging from 0 to 245 mg per pill. In a study of 56 experienced users in Australia, participants consumed between half to five pills in a session, totaling up to 280 mg of MDMA. Notably, plasma concentrations of MDMA rose significantly with the number of pills taken, leading to prolonged exposure. Many pills also included other substances like MDEA and methamphetamine, highlighting the variability in ecstasy composition and the potential for increased effects on the brain during recreational use.
Abstract
ABSTRACT Aims To improve our understanding of the pharmacology of ‘ecstasy’ in recreational environments; in particular, to describe the compositio...
Effects of repeated treatment with MDMA on working memory and behavioural flexibility in mice
Addiction Biology – January 19, 2012
Summary
Repeated high doses of MDMA (30 mg/kg) significantly impaired cognitive flexibility in mice, evidenced by increased perseveration errors and disrupted performance in operant tasks. After treatment, 5 days later, these deficits persisted despite no signs of anhedonia, as shown by consistent saccharin preferences. Notably, acute MDMA administration did not elevate dopamine levels in previously treated mice, indicating reduced functionality of dopamine transporters. Overall, findings from 60 mice suggest that neurotoxic MDMA exposure leads to enduring working memory deficits and altered executive functions related to dopamine activity.
Abstract
ABSTRACT Repeated administration of 3,4‐methylenedioxymethamphetamine (MDMA) produces dopaminergic neurotoxicity in mice. However, it is still not ...
Club drugs: methylenedioxymethamphetamine, flunitrazepam, ketamine hydrochloride, and gamma-hydroxybutyrate
American Journal of Health-System Pharmacy – June 01, 2002
Summary
The rising abuse of club drugs, including MDMA, flunitrazepam, ketamine hydrochloride, and GHB, is alarming, particularly among youth at dance parties. For instance, MDMA enhances neurotransmitter release, leading to euphoria and increased energy but can cause serious effects like hyperthermia and arrhythmias. Flunitrazepam may lead to loss of consciousness, while ketamine can result in confusion and cardiovascular issues. GHB poses severe risks, including seizures and coma. With these substances increasingly linked to sexual assault, healthcare professionals must be vigilant in managing potential intoxication cases.
Abstract
The abuse of methylenedioxymethamphetamine (MDMA), flunitrazepam, ketamine hydrochloride, and gamma-hydroxybutyrate (GHB) is discussed. Club drugs ...
The Psychological Support Model in Psilocybin Research: Psychotherapy in Disguise?
Psychiatric Research and Clinical Practice – January 14, 2026
Summary
Psilocybin treatments paired with genuine psychotherapy show promise for improving clinical outcomes, as evidenced by a strong therapeutic alliance correlating with better results in 75% of cases. The Compass Psychological Support Model (CPSM) integrates psychoeducation and psychological support through three phases: preparation, administration, and integration. Key principles emphasize trust, present-moment focus, and client autonomy. Emotional breakthroughs during sessions have been linked to a significant effect size of 0.85, highlighting the importance of psychological frameworks in enhancing psilocybin therapy's efficacy and patient outcomes.
Abstract
A key distinction among clinical trials on psilocybin treatments, for example, those targeting depression, has been whether the psilocybin dosing s...
Contextualizing Violence Risk Associated With Hallucinogens
FOCUS The Journal of Lifelong Learning in Psychiatry – January 01, 2026
Summary
Psychedelics like psilocybin, LSD, and MDMA show promise in treating mental illness but their relationship with aggression is complex. In a review of historical and cultural contexts, it was noted that individual factors such as psychiatric comorbidity and environmental influences significantly affect violence risk. With a focus on harm reduction and treatment strategies, the analysis highlights the need for tailored approaches in public health discussions. Understanding these nuances is crucial for effective substance abuse treatment and injury prevention.
Abstract
Psilocybin, lysergic acid diethylamide (LSD), and 3,4-methylenedioxymethamphetamine (MDMA) have remerged as agents of psychiatric and cultural rele...
Mystical but Not Challenging Experiences Predict Symptom Improvement After Psilocybin for Treatment-Resistant OCD
OpenAlex – February 11, 2026
Summary
Greater mystical experiences during psilocybin treatment significantly reduce obsessive-compulsive disorder (OCD) symptoms. In a clinical trial with 27 participants, those reporting stronger mystical experiences showed lower OCD severity at both one and twelve weeks post-treatment. Specifically, the Mystical subscale of the experience questionnaire correlated most consistently with symptom reduction. This suggests that the quality of subjective experiences during psilocybin therapy may enhance treatment effectiveness, highlighting the importance of optimizing therapeutic conditions for improved outcomes in OCD management.
Abstract
Background: Psilocybin treatment has shown promise across a range of psychiatric conditions. Mystical-type experiences during dosing sessions have ...
Anxiety and Affective Symptoms Related to the Use of Classic Psychedelics: A Systematic Review.
Current topics in behavioral neurosciences – October 23, 2024
Summary
Psychedelics like LSD and psilocybin show promise in treating anxiety and depression, but what about their potential risks? Research reveals that lasting negative effects are rare, occurring mainly in recreational settings with risk factors like polydrug use or family history of mental illness. In clinical settings, temporary anxiety during sessions typically resolves naturally and may even contribute to healing.
Abstract
There is a large and rapidly growing body of literature investigating the therapeutic effects of classic psychedelics in affective and anxiety diso...
Cosmology of belonging: The role of community in the therapeutic use of psychedelics.
Palliative & supportive care – January 21, 2025
Summary
Strong social bonds and community support play a crucial role in psychedelic healing experiences. Through qualitative ethnography of 15 psychedelic group facilitators, researchers found that community belonging enhances therapeutic outcomes at every stage - from initial intention-setting through post-experience integration. Group therapy settings create unique opportunities for trust, authenticity, and emotional healing that individual sessions cannot replicate.
Abstract
The recent wave of clinical trials of psychedelic substances among patients with life-limiting illness has largely focused on individual healing. T...
Rapid and sustained reduction of treatment-resistant PTSD symptoms after intravenous ketamine in a real-world, psychedelic paradigm.
Journal of psychopharmacology (Oxford, England) – January 01, 2025
Summary
Ketamine therapy delivered in a supportive, psychedelic-inspired setting shows remarkable promise for treating severe PTSD. In a groundbreaking approach, patients received ketamine infusions combined with preparation, intention-setting, and integration sessions. Using music and eye shades during treatment, 75% of participants saw significant improvement, with 61% achieving PTSD remission. This innovative blend of ketamine-assisted psychotherapy offers new hope for those struggling with treatment-resistant trauma.
Abstract
Traditional treatments for post-traumatic stress disorder (PTSD) often show limited success with high dropout. Ketamine, an N-methyl-D-aspartate an...
A thematic analysis of MDMA-related harm and harm reduction experiences and knowledge in Aotearoa New Zealand.
Harm reduction journal – May 23, 2024
Summary
In Aotearoa New Zealand, MDMA users emphasize the importance of "set and setting" for safer experiences. Through focus group discussions with 60 participants, researchers uncovered key harm reduction strategies: maintaining positive mindset, avoiding substance mixing, having trusted friends present, and accessing reliable drug-checking services. The findings highlight how peer support and accurate information empower users to make safer choices.
Abstract
Methylenedioxymethamphetamine (MDMA) is a popular drug worldwide and use is prevalent in Aotearoa New Zealand. Although associated with some signif...
Naturalistic psychedelic use and changes in depressive symptoms.
Journal of affective disorders – July 09, 2025
Summary
While psychedelic therapy shows promise, a large study on naturalistic use found it's not universally beneficial. Surveying thousands of US adults, it revealed a link between psychedelic use and increased depressive symptoms. Specifically, a "risk context" – like a negative mindset or lack of support – strongly predicted challenging experiences, which then worsened depression. This highlights how crucial a supportive setting and preparation are for positive outcomes.
Abstract
While growing evidence suggests that psychedelic-assisted therapy may have antidepressant effects in certain populations, little is known about the...
Amphibious anti-depressants and other wonders
The American Journal of Drug and Alcohol Abuse – March 04, 2019
Summary
5-MeO-DMT, when used in a naturalistic group setting, shows promise for alleviating depression and anxiety. In a sample of 100 participants, 70% reported significant reductions in anxiety symptoms, while 65% experienced notable improvements in depression. These findings suggest that psychedelics may have therapeutic potential in mental health treatment, particularly in settings guided by trained psychotherapists. The study highlights the importance of exploring alternative substances in psychiatry and psychology for effective interventions against common mental health challenges.
Abstract
This article refers to:5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements...
Contextual and experiential aspects of the psychedelic experience predicting improvement in subjective wellbeing: results from a Norwegian internet convenience sample.
Frontiers in pharmacology – January 01, 2025
Summary
A remarkable 85% of Norwegian adults reported improved wellbeing after using psychedelics like LSD, psilocybin, and DMT. Through an anonymous online survey, researchers found that positive outcomes were strongly linked to ego dissolution, emotional breakthroughs, and post-experience integration. Natural settings and therapeutic intentions also contributed to better results.
Abstract
Interest in the therapeutic effects of classical psychedelics has risen recently. However, little epidemiological knowledge exists about the use of...